Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...
CymaBay Therapeutics
MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis
The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...
Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment
Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...
Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial
Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...
Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires
Gilead Sciences (NASDAQ: GILD) has moved one step closer to finalizing its cash tender offer...